Karakolevska Ilova, Marija (2019) Luminal A: What can we expect in premenopausal patients? Good or bad news? In: 6th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology, Sibenik,Croatia. (Unpublished)
![[thumbnail of Luminal A breast cancer -Masterclass 2019.pdf]](/style/images/fileicons/text.png) |
Text
Luminal A breast cancer -Masterclass 2019.pdf - Presentation Download (297kB) |
|
Text
programa Sibenik 2019.pdf - Presentation Download (264kB) |
Abstract
Breast cancer subtypes are associated with distinct patterns of metastatic spread with notable differences in survival after relapse. Median durations of survival with distant metastasis in average are 2.2 (luminal A), 1.6 (luminal B), 1.3(luminal/HER2), 0.7 (HER2 enriched), and 0.5 years (basal-like; P < .001). The question is still opened about the first treatment of Luminal A/ 2-2,5sm, N1a( 1+ l.n) breast cancer: hormone v.s chemotherapy, RT v.s no RT? Are we overrtreating or sub treating these patients?
| Item Type: | Conference or Workshop Item (Speech) |
|---|---|
| Uncontrolled Keywords: | Luminal A , breast cancer, premenopausal women |
| Subjects: | Medical and Health Sciences > Clinical medicine |
| Divisions: | Faculty of Medical Science |
| Depositing User: | Marija Karakolevska |
| Date Deposited: | 03 May 2022 10:17 |
| Last Modified: | 03 May 2022 10:17 |
| URI: | https://eprints.ugd.edu.mk/id/eprint/29651 |
Actions (login required)
 |
View Item |